RJA
LUMO

Raymond James & Associates’s Lumos Pharma, Inc. Common Stock LUMO Stock Holding History

Raymond James & Associates’s Portfolio LUMO Stock Details LUMO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q3 		– Sell
-3,447
Closed -$148K – 3733
2018
Q2 		$148K Buy
3,447
+19
+0.6% +$870 ﹤0.01% 3338
2018
Q1 		$224K Buy
3,428
+142
+4% +$10.1K ﹤0.01% 3073
2017
Q4 		$240K Buy
+3,286
New +$272K ﹤0.01% 2954
2017
Q1 		– Sell
-1,491
Closed -$138K – 3420
2016
Q4 		$138K Sell
1,491
-56
-4% -$6.31K ﹤0.01% 2979
2016
Q3 		$209K Sell
1,547
-155
-9% -$15.4K ﹤0.01% 2826
2016
Q2 		$173K Sell
1,702
-289
-15% -$35.8K ﹤0.01% 2701
2016
Q1 		$326K Buy
1,991
+642
+48% +$130K ﹤0.01% 2279
2015
Q4 		$442K Sell
1,349
-56
-4% -$18.2K ﹤0.01% 2051
2015
Q3 		$453K Buy
1,405
+15
+1% +$6.59K ﹤0.01% 1965
2015
Q2 		$554K Buy
1,390
+94
+7% +$39.9K ﹤0.01% 2042
2015
Q1 		$638K Sell
1,296
-292
-18% -$113K ﹤0.01% 1920
2014
Q4 		$568K Sell
1,588
-296
-16% -$88.1K ﹤0.01% 1881
2014
Q3 		$363K Buy
1,884
+314
+20% +$69K ﹤0.01% 1967
2014
Q2 		$375K Sell
1,570
-56
-3% -$11.4K ﹤0.01% 1967
2014
Q1 		$416K Sell
1,626
-1,022
-39% -$312K ﹤0.01% 1863
2013
Q4 		$525K Sell
2,648
-1,392
-34% -$248K ﹤0.01% 1647
2013
Q3 		$683K Sell
4,040
-33
-0.8% -$5.31K 0.01% 1447
2013
Q2 		$723K Buy
+4,073
New +$577K 0.01% 1332

Other funds holding LUMO

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Connor, Clark & Lunn Investment Management (CC&L)
Connor, Clark & Lunn Investment Management (CC&L) Vancouver, British Columbia, Canada $43.4B AUM 51.29% 1-Year Est. Return
PAM
Panagora Asset Management Boston, Massachusetts $26.7B AUM 36.4% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Raymond James & Associates's LUMO Position: Q3 2018 in Review

Raymond James & Associates sold out of Lumos Pharma, Inc. Common Stock (LUMO) in Q3 2018, closing a stake of 3,447 shares — an estimated $148K sold.

Raymond James & Associates first reported a position in LUMO in Q2 2013 and held it in 18 quarters. The position peaked at $723K in Q2 2013. 92 funds tracked by Wall St. Rank hold LUMO as of Q3 2018.

  • Raymond James & Associates reported no remaining Lumos Pharma, Inc. Common Stock position as of Q3 2018 after selling out during the quarter.
  • Raymond James & Associates sold 3,447 Lumos Pharma, Inc. Common Stock shares in Q3 2018, an estimated $148K.
  • Raymond James & Associates first reported a position in Lumos Pharma, Inc. Common Stock in Q2 2013 and held it in 18 quarters.
  • Raymond James & Associates's Lumos Pharma, Inc. Common Stock position peaked at $723K in Q2 2013.
  • 92 funds tracked by Wall St. Rank held Lumos Pharma, Inc. Common Stock as of Q3 2018.

Based on Raymond James & Associates's 13F filing for Q3 2018, filed 14 Nov 2018.